PTD-DBM
PTD-DBM (Wnt Activator Peptide)
PTD-DBM is a cell-permeable peptide consisting of a protein transduction domain (PTD) fused to a Dishevelled-binding motif (DBM), engineered to activate the canonical Wnt/β-catenin signaling pathway. It is primarily investigated for its ability to promote hair follicle neogenesis and treat androgenetic alopecia by displacing the inhibitory interaction between Dishevelled (Dvl) and CXXC-type zinc finger protein 5 (CXXC5). Research interest has also extended to wound healing and tissue regeneration applications.
Mechanism of Action
PTD-DBM disrupts the protein-protein interaction between CXXC5 and Dishevelled (Dvl), a negative feedback regulator of Wnt/β-catenin signaling. By competitively binding to the PDZ domain of Dvl, the peptide releases CXXC5-mediated suppression, thereby allowing downstream β-catenin to translocate to the nucleus and drive transcription of Wnt target genes involved in follicle cycling, keratinocyte proliferation, and dermal papilla activation. This mechanism effectively reactivates a quiescent hair follicle stem cell niche without directly agonizing Wnt ligand receptors.
Evidence by Health Goal(3 goals)
Dosing Protocols
Applied to cleansed, dry scalp; ideally in the evening
Cycle: 12 weeks on, 4 weeks off
Often co-formulated with valproic acid (a Wnt pathway amplifier) in preclinical studies; penetration enhancers such as ethanol or propylene glycol are commonly included. Human clinical data remain limited; protocols are extrapolated from murine studies.
Consistent day of the week; may be combined with microneedling for enhanced delivery
Cycle: 8-12 weeks on, 4 weeks off
Reconstitute in bacteriostatic saline; injection-site delivery maximizes local Wnt activation and reduces systemic exposure. Use of sterile technique is mandatory. Clinical dosing in humans is not formally established.
Safety & Side Effects
PTD-DBM has a relatively favorable local safety profile in preclinical (murine) studies, with no significant systemic toxicity observed at therapeutic doses; however, robust human safety and efficacy data are absent, making this an experimental compound used outside any formal regulatory approval. Because Wnt/β-catenin is a proto-oncogenic pathway, the theoretical long-term risk of promoting dysregulated cell proliferation with excessive or prolonged use warrants caution, and use should be avoided in individuals with personal or family history of skin malignancies.
Possible Side Effects
- !Local injection-site irritation, erythema, or transient swelling
- !Scalp pruritus or mild burning sensation with topical application
- !Transient shedding phase (telogen effluvium-like event) during early treatment as follicles cycle
- !Contact dermatitis or hypersensitivity reaction to formulation excipients
- !Theoretical risk of off-target Wnt pathway activation in adjacent tissue if used at high doses
- !Headache or mild systemic symptoms reported anecdotally with injection use
- !Potential for local hyperpigmentation at repeated injection sites
Interactions
- -Valproic acid (GSK-3β inhibitor): synergistic Wnt pathway activation reported in preclinical studies — combined use may amplify effects and increase risk of off-target proliferative signaling
- -Other Wnt/β-catenin activators (e.g., lithium, SB-216763): additive pathway stimulation; concurrent use not recommended without close monitoring
- -Topical corticosteroids: may antagonize follicle-stimulating effects by suppressing keratinocyte proliferation and local immune signaling
- -Immunosuppressant medications: altered local immune environment may unpredictably modify peptide efficacy or local tolerability
- -Minoxidil: mechanistically distinct but commonly co-used for alopecia; no direct pharmacokinetic interaction known, though combined pro-proliferative signals are theoretically additive
Cost & Where to Buy
PTD-DBM is available only from specialty research peptide vendors; purity and pricing vary widely. Topical formulation costs depend heavily on compounding fees and excipient choice. Injection-grade lyophilized peptide at research vendors typically runs $40-120 per 1-5 mg vial; monthly cost reflects typical usage cycle.
Search on Amazon